Tierney David S
Known title: DirectorCIK: 0001292636
Tierney David S's purchase track record
How the stock did after each of Tierney David S's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since November 30, 2021
Stock higher 6 months later
67%
3 months: 67%
Median 6-month return
+6.6%
3 months: +30.1%
Beat the S&P 500
67%
median +5.3% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/9/2023 | ZVRA | $21K | +30.1% | +24.0% | +13.6% |
| 5/25/2022 | ZVRA | $9K | +39.4% | +6.6% | +1.2% |
| 11/30/2021 | ZVRA | $16K | -27.3% | -40.9% | -9.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ZVRA | ▲ Buy | Open Market | 5,000 | $21K | 3/9/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 2,000 | $9K | 5/25/2022 | View on chart |
| ZVRA | ▲ Buy | Open Market | 2,000 | $16K | 11/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price
Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price. Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.